Imugene Ltd
ASX:IMU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Imugene Ltd
ASX:IMU
|
AU |
|
Neuland Laboratories Ltd
NSE:NEULANDLAB
|
IN |
|
Champion Real Estate Investment Trust
HKEX:2778
|
HK |
|
O Bank Co Ltd
TWSE:2897
|
TW |
|
BNP Paribas SA
PAR:BNP
|
FR |
|
C
|
Campbell Soup Co
SWB:CSC
|
US |
|
H
|
Hydrogene De France SA
PAR:HDF
|
FR |
|
Johnson Service Group PLC
LSE:JSG
|
UK |
|
S
|
Shenzhen FRD Science & Technology Co Ltd
SZSE:300602
|
CN |
|
Abundante Ltd
SGX:570
|
SG |
|
Corporacion Acciona Energias Renovables SA
MAD:ANE
|
ES |
|
Bega Cheese Ltd
ASX:BGA
|
AU |
|
G
|
Greenland Resources Inc
OTC:GRLRF
|
CA |
|
Chang Hwa Commercial Bank Ltd
TWSE:2801
|
TW |
|
S
|
STWC Holdings Inc
OTC:STWC
|
US |
|
H
|
Highlands REIT Inc
OTC:HHDS
|
US |
|
S
|
Shengjing Bank Co Ltd
HKEX:2066
|
CN |
|
Spirax-Sarco Engineering PLC
LSE:SPX
|
UK |
Imugene Ltd
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in developing immunotherapies that seeks to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness the body’s immune system against cancerous tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with care drugs and immunotherapies such as chimeric antigen receptor T cells (CAR T’s) for solid tumors. Its PD-1 B-cell immunotherapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies for the treatment of cancers. Its clinical trial candidates include VAXinia (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in developing immunotherapies that seeks to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness the body’s immune system against cancerous tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with care drugs and immunotherapies such as chimeric antigen receptor T cells (CAR T’s) for solid tumors. Its PD-1 B-cell immunotherapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies for the treatment of cancers. Its clinical trial candidates include VAXinia (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.
